Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that the U.S. Food and Drug Administration has approved LYTENAVA (bevacizumab-vikg) for the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE